Elicio Therapeutics Statistics
Share Statistics
Elicio Therapeutics has 10.79M shares outstanding. The number of shares has increased by 5.58% in one year.
| Shares Outstanding | 10.79M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.15% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 8.13M |
| Failed to Deliver (FTD) Shares | 1.54K |
| FTD / Avg. Volume | 5.89% |
Short Selling Information
The latest short interest is 42.96K, so 0.4% of the outstanding shares have been sold short.
| Short Interest | 42.96K |
| Short % of Shares Out | 0.4% |
| Short % of Float | 0.53% |
| Short Ratio (days to cover) | 2.49 |
Valuation Ratios
The PE ratio is -1.2 and the forward PE ratio is -1.95.
| PE Ratio | -1.2 |
| Forward PE | -1.95 |
| PS Ratio | 0 |
| Forward PS | 3.3 |
| PB Ratio | 3.71 |
| P/FCF Ratio | -1.29 |
| PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Elicio Therapeutics Inc..
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.67, with a Debt / Equity ratio of 0.
| Current Ratio | 1.67 |
| Quick Ratio | 1.67 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | -33.75 |
Financial Efficiency
Return on equity (ROE) is -3.09% and return on capital (ROIC) is -195.43%.
| Return on Equity (ROE) | -3.09% |
| Return on Assets (ROA) | -1.3% |
| Return on Capital (ROIC) | -195.43% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -1.10M |
| Employee Count | 32 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 14.96% in the last 52 weeks. The beta is 0, so Elicio Therapeutics 's price volatility has been lower than the market average.
| Beta | 0 |
| 52-Week Price Change | 14.96% |
| 50-Day Moving Average | 5.16 |
| 200-Day Moving Average | 5.93 |
| Relative Strength Index (RSI) | 61.98 |
| Average Volume (20 Days) | 26.08K |
Income Statement
| Revenue | n/a |
| Gross Profit | -1.17M |
| Operating Income | -35.74M |
| Net Income | -35.20M |
| EBITDA | -32.97M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -6.96 |
Balance Sheet
The company has 12.89M in cash and 6.92M in debt, giving a net cash position of 5.98M.
| Cash & Cash Equivalents | 12.89M |
| Total Debt | 6.92M |
| Net Cash | 5.98M |
| Retained Earnings | -142.20M |
| Total Assets | 38.39M |
| Working Capital | 21.63M |
Cash Flow
In the last 12 months, operating cash flow was -32.69M and capital expenditures -66.00K, giving a free cash flow of -32.76M.
| Operating Cash Flow | -32.69M |
| Capital Expenditures | -66.00K |
| Free Cash Flow | -32.76M |
| FCF Per Share | -6.48 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ELTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -114.66% |
| FCF Yield | -50.01% |
Analyst Forecast
The average price target for ELTX is $9.5, which is 56.5% higher than the current price. The consensus rating is "Buy".
| Price Target | $9.5 |
| Price Target Difference | 56.5% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
Stock Splits
The last stock split was on Jun 2, 2023. It was a backward split with a ratio of 1:10.
| Last Split Date | Jun 2, 2023 |
| Split Type | backward |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | -8.56 |
| Piotroski F-Score | 2 |